论文部分内容阅读
目的 探讨脂肝泰胶囊治疗高脂血症性脂肪肝的作用机制。方法 采用高脂饮食喂饲大鼠复制脂肪肝模型 ,实验分组为模型组、脂肝泰高剂量组、脂肝泰低剂量组、东宝肝泰对照组和正常对照组。以高、低剂量脂肝泰和东宝肝泰进行干预 ,然后测定各组大鼠血浆ET - 1的含量。结果 模型组大鼠血浆ET - 1的含量与正常组差异有显著性意义 (P <0 0 1 )。各治疗组大鼠血浆ET - 1的含量与模型组间差异有显著性意义 (P <0 0 5) ;脂低组血浆ET- 1含量与脂高组、对照组间差异有显著性意义 (P <0 0 5)。结论 脂肝泰胶囊可通过降低血浆ET - 1的含量发挥抗肝损伤的作用
Objective To investigate the mechanism of Zhigantai capsule in treating fatty liver with hyperlipidemia. Methods Fatty liver rats were fed with a high-fat diet. The experimental groups were divided into model group, high-fat group, Zhigantai low-dose group, Dongbaogantai control group and normal control group. Intervention was made with high and low dose of ZhiGanTai and DongbaoGanTai, and then the content of plasma ET - 1 in each group was measured. Results The plasma levels of ET - 1 in the model group were significantly different from those in the normal group (P <0.01). The content of plasma ET - 1 in each treatment group was significantly different from that in the model group (P <0.05). The plasma ET - 1 level in the lipid - low group was significantly different from that in the hyperlipidemia group and the control group P <0 0 5). Conclusion ZhiGanTai Capsule can play an anti - hepatic injury role by decreasing the content of plasma ET - 1